View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Nivolumab 360 / Ipilimumab 1, Non-Small Cell Lung Cancer, Maintenance
Protocol-ID: 1671 V1.0 (Mini), NIVO360/IPIL1, NSCLC, maint.Indication(s)
- Lung Carcinoma, Non-Small Cell; ICD-10 C34.-
Links
- Gainor, JF. Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2, ASCO 2020 [ASCO Abstracts doi]
- Ramalingam, SS. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1, ASCO 2020 [ASCO Abstracts doi]
- Reck, M. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA, ASCO 2020 [ASCO Abstracts doi]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 24.12.2021